Magenta reports Phase I/II data for MGTA-456

Magenta Therapeutics Inc. (Cambridge, Mass.) reported data from the Phase II portion of an open-label, U.S. Phase I/II trial showing MGTA-456 as a stand-alone hematopoietic

Read the full 252 word article

User Sign In